



Invitation to presentation of Acarix´s third quarter report

Acarix will publish its third quarter results on Thursday 9 November 2023 at 08.00 am (CEST). A live webcast will be held at 14.00 (CEST) the same day, where Acting CEO Fred Colen and CFO Christian Lindholm will present the report. The presentation ends with a Q&A together with Redeye's analysts, where you can ask the company questions via the form on the live page.

The webcast will be available at <https://www.redeye.se/events/948387/live-q-acarix-q3-report?tab=abouttheevent>

The presentation will be available at <https://www.acarix.com/for-investors/investor-presentations> after publication of the report.

For more information contact:

Fred Colen, acting CEO, email fred.colen@acarix.com

Christian Lindholm, CFO, phone +46 705 118333, email christian.lindholm@acarix.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of coronary artery disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. The CADScor System has been used on more than 29,000 patients and is recommended as a first-line diagnostic aid as outlined in the clinical workflow developed in collaboration with the American College of Cardiology (ACC). Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Erik Penser Bank AB (+46 8 463 83 00, certifiedadviser@penser.se) is Certified Advisor of Acarix. For more information, please visit www.acarix.com.

Attachments

[Invitation to presentation of Acarix´s third quarter report](#)